



J. B. Chemicals & Pharmaceuticals Limited

Regd. Office : Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai 400 030.
 Phone: 022-24822222/24930918 Fax : 022 – 2493 0534/ 2493 9633
 CIN : L24390MH1976PLC019380 Website: www.jbcpl.com E-mail : secretarial@jbcpl.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30/06/2014

(Rs. in lakhs)

Sl.No.	PART I - Particulars	Quarter ended			Year ended
		30/06/2014	31/03/2014	30/06/2013	31/03/2014
		Unaudited	Audited	Unaudited	Audited
1	Income from Operations				
	a. Net sales (Net of excise duty)	25,671.21	22,360.79	22,916.67	93,443.47
	b. Other Operating Income	589.07	498.99	606.13	2,209.92
	Total Income from Operations (Net) (a+b)	26,260.28	22,859.78	23,522.80	95,653.39
2	Expenses				
	a. Cost of materials consumed	8,338.64	7,547.46	7,825.35	31,078.57
	b. Purchases of stock-in-trade	2,402.03	2,170.45	2,239.14	7,677.06
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	437.46	(578.34)	(207.48)	(1,074.92)
	d. Employees benefits expense	3,718.27	3,292.57	3,390.01	13,184.59
	e. Depreciation and amortization expense	990.00	616.51	750.00	2,716.51
	f. Exchange Fluctuation Transactional (Gain)/Loss	(49.45)	(0.08)	3.58	479.29
	g. Other Expenses	6,578.02	8,651.43	6,233.38	29,299.51
	Total Expenses	22,414.97	21,700.00	20,233.98	83,360.61
3	Profit from Operations before Other Income, Finance Cost and exceptional item (1-2)	3,845.31	1,159.78	3,288.82	12,292.78
4	Other Income	173.96	836.90	151.52	3,753.77
5	Profit from Ordinary Activities before Finance Cost and exceptional item (3+4)	4,019.27	1,996.68	3,440.34	16,046.55
6	Finance Cost	132.57	86.23	146.88	612.70
7	Profit from Ordinary Activities after Finance Cost but before Exchange Fluctuation Translation Gain / (Loss) (5-6)	3,886.70	1,910.45	3,293.46	15,433.85
8	Exchange Fluctuation Translation Gain / (Loss)	368.77	584.95	(544.16)	414.93
9	Profit from Ordinary Activities after Exchange Fluctuation Translation Gain / (Loss) but before Exceptional item (7+-8)	4,255.47	2,495.40	2,749.30	15,848.78
10	Exceptional Item: Revision of purchase price in respect of Sale of Russia-CIS OTC Business Undertaking	-	-	-	(6,450.00)
11	Profit before Tax (9-10)	4,255.47	2,495.40	2,749.30	9,398.78
12	Tax expenses	1,076.37	352.21	716.76	2,556.23
13	Net Profit/(Loss) after Tax (11-12)	3,179.10	2,143.19	2,032.54	6,842.55
14	Paid Up Equity Share Capital (Face Value Rs.2/-)	1,695.40	1,694.63	1,694.24	1,694.63
15	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	103,086.53
16	Earning per share(EPS) (of Rs. 2/- each not annualised)				
	(1) Basic	3.75	2.53	2.40	8.08
	(2) Diluted	3.75	2.53	2.40	8.07

Sl. No.	PART II - Particulars	Quarter ended			Year ended
		30/06/2014	31/03/2014	30/06/2013	31/03/2014
		Unaudited	Audited	Unaudited	Audited
A	PARTICULARS OF SHAREHOLDING				
1	Public Shareholding				
	- Number of Shares	37,453,963	37,405,427	37,385,603	37,405,427
	- Percentage of shareholding	44.18	44.15	44.13	44.15
2	Promoters and Promoter Group Shareholding				
	a) Pledged/Encumbered				
	- Number of Shares	-	-	-	-
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-
	b) Non-encumbered				
	- Number of Shares	47,315,787	47,326,198	47,326,197	47,326,198
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	55.82	55.85	55.87	55.85

B INVESTOR COMPLAINTS

Particulars	3 Months ended 30/06/2014
Pending at the beginning of the quarter	1
Received during the quarter	5
Disposed of during the quarter	6
Remaining unresolved at the end of the quarter	0

NOTES

1. The above financial results have been reviewed by the audit committee and approved by the board of directors at its meeting held on August 5, 2014.
2. The statutory auditors have carried out limited review of the above financial results for the quarter ended on June 30, 2014.
3. The net sales for the quarter are strictly not comparable due to the company's wholly owned subsidiary in Dubai commencing sales and distribution of the products in Russia-CIS countries during the quarter. This subsidiary will also undertake some of the expenses. Hence this arrangement is not expected to have significant impact on the company.
4. The company has provided depreciation based on expected life as per Schedule II to the Companies Act, 2013.
5. The company is engaged in a single segment of activity viz. Pharmaceuticals.
6. The figures in respect of the results for preceding quarter ended on March 31, 2014 are balancing figures between the audited financial results in respect of the full financial year ended on March 31, 2014 and the published year to date figures up to the third quarter ended on December 31, 2013.
7. The previous quarter's figures have been regrouped/re-stated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.



Place : Mumbai
Date : August 5, 2014

J.B.Mody
Chairman & Managing Director